A decade-long clinical experience on the prophylactic use of activated prothrombin complex concentrate in acquired haemophilia A: a case series from a tertiary care …

A Árokszállási, K Rázsó, P Ilonczai, Z Oláh… - Blood Coagulation & …, 2018 - journals.lww.com
In acquired haemophilia A (AHA), risk for recurrent bleeding exists until the inhibitor is
detectable. Thus, patients with persisting inhibitor may benefit from prophylaxis with …
被引用次数：14 相关文章

[引用][C] A decade-long clinical experience on the prophylactic use of activated prothrombin complex concentrate in acquired haemophilia A: a case series from a tertiary …

A Árokszállási, K Rázsó, P Ilonczai… - Blood Coagulation & …, 2018 - ingentaconnect.com
In acquired haemophilia A (AHA), risk for recurrent bleeding exists until the inhibitor is
detectable. Thus, patients with persisting inhibitor may benefit from prophylaxis with …

A decade-long clinical experience on the prophylactic use of activated prothrombin complex concentrate in acquired haemophilia A: a case series from a tertiary care …

A Árokszállási, K Rázsó, P Ilonczai, Z Oláh… - Blood Coagulation & …, 2018 - europepmc.org
: In acquired haemophilia A (AHA), risk for recurrent bleeding exists until the inhibitor is
detectable. Thus, patients with persisting inhibitor may benefit from prophylaxis with …

A decade-long clinical experience on the prophylactic use of activated prothrombin complex concentrate in acquired haemophilia A: a case series from a tertiary care …

A Árokszállási, K Rázsó, P Ilonczai… - … & fibrinolysis: an …, 2018 - pubmed.ncbi.nlm.nih.gov
: In acquired haemophilia A (AHA), risk for recurrent bleeding exists until the inhibitor is
detectable. Thus, patients with persisting inhibitor may benefit from prophylaxis with …